Simple Analysis Used in Diagnosis and Follow-up of Schizophrenic Patients

Nour El-Dien, Faten A.; El-Nahas, Reham G.; El-Nahas, Ahmed G.

doi:https://doi.org/10.1155/JAMMC/2006/79038

Journal of Analytical Methods in Chemistry

On this page

Abstract References Copyright Related Articles

Open Access

Volume 2006 | Article ID 079038 | https://doi.org/10.1155/JAMMC/2006/79038

Simple Analysis Used in Diagnosis and Follow-up of Schizophrenic Patients

Faten A. Nour El-Dien,¹Reham G. El-Nahas,²and Ahmed G. El-Nahas³

Received31 Jul 2006

Accepted06 Sept 2006

Published30 Nov 2006

Abstract

Dopamine acts as neurotransmitter in the central and peripheral sympathetic nervous system. Determination of dopamine (DO) was performed by spectrophotometric analysis depending on the formation of new colored compound. The proposed procedure was efficient in quantitative determination of DO as pure material in pharmaceutical preparations and in urine samples. DO concentration in urine sample of patient confirms the affection with schizophrenia and the proposed procedure was used to facilitate diagnosis and followup of schizophrenic patients. It is recommended to apply the proposed procedures as routine analysis in pharmaceutical companies for quality control and in analytical laboratories to diagnose and follow up schizophrenia.

References

J. Chen, Y.-P. Shi, and J.-Y. Liu, “Determination of noradrenaline and dopamine in Chinese herbal extracts from Portulaca oleracea L. by high-performance liquid chromatography,” Journal of Chromatography A, vol. 1003, no. 1-2, pp. 127–132, 2003.
View at: Publisher Site | Google Scholar
J. Szopa, G. Wilczyński, O. Fiehn, A. Wenczel, and L. Willmitzer, “Identification and quantification of catecholamines in potato plants (Solanum tuberosum) by GC–MS,” Phytochemistry, vol. 58, no. 2, pp. 315–320, 2001.
View at: Publisher Site | Google Scholar
P. Loutala, Catechol O-Methyltransferase: Glucuronidation of Inhibitors and Methylation of Substrates, University of Helsinki, Helsinki, Finland, 2000.
View at: Google Scholar
M. C. Rodriguez, J. A. Obeso, and C. W. Olanow, “Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection,” Annals of Neurology, vol. 44, no. 3, supplement 1, pp. S175–S188, 1998.
View at: Google Scholar
P. G. Strange, published October 2000, http://www.tocris.com/.
Puttaswamy, R. V. Jagadeesh, and N. Vaz, “Oxidation of some catecholamines by sodium N-chloro-p-toluenesulfonamide in acid medium: a kinetic and mechanistic approach,” Central European Journal of Chemistry, vol. 3, no. 2, pp. 326–346, 2005.
View at: Publisher Site | Google Scholar
J. Coello, S. Maspoch, and N. Villegas, “Simultaneous kinetic-spectrophotometric determination of levodopa and benserazide by bi- and three-way partial least squares calibration,” Talanta, vol. 53, no. 3, pp. 627–637, 2000.
View at: Publisher Site | Google Scholar
P. Nagaraja, K. C. S. Murthy, K. S. Rangappa, and N. M. M. Gowda, “Spectrophotometric methods for the determination of certain catecholamine derivatives in pharmaceutical preparations,” Talanta, vol. 46, no. 1, pp. 39–44, 1998.
View at: Publisher Site | Google Scholar
P. Nagaraja, R. A. Vasantha, and K. R. Sunitha, “A new sensitive and selective spectrophotometric method for the determination of catechol derivatives and its pharmaceutical preparations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 25, no. 3-4, pp. 417–424, 2001.
View at: Publisher Site | Google Scholar
P. Nagaraja, K. C. S. Murthy, H. S. Yathirajan, and B. M. Mohan, “Rapid spectrophotometric determination of dopamine hydrochloride with chloramine-T,” Indian Journal of Pharmaceutical Sciences, vol. 60, no. 2, pp. 99–101, 1998.
View at: Google Scholar
N. A. A. Rashwan, “Analytical studies on reaction of iodine and some iron (III) chelates with some phenolic compounds,” M.Sc. thesis, Cairo University, Giza, 1992.
View at: Google Scholar
A. Afkhami and H. A. Khatami, “Determination of some catecholamines based on their reaction with periodate,” Journal of Analytical Chemistry, vol. 58, no. 2, pp. 135–138, 2003.
View at: Publisher Site | Google Scholar
J. Hanai and T. Takeda, “The addition of dopamine determination to the measurement of acidic catecholamine metabolites in urine screening for neuroblastoma,” Screening, vol. 4, no. 2, pp. 91–100, 1995.
View at: Google Scholar
E. Brandsteterova, P. Kubalec, I. Skacani, and I. Balazovjech, “HPLC-ED determination of catecholamines and their metabolites in urine,” Neoplasma, vol. 41, no. 4, pp. 205–211, 1994.
View at: Google Scholar
W. J. Burke, H. D. Chung, and S. W. Li, “Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4- dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography,” Analytical Biochemistry, vol. 273, no. 1, pp. 111–116, 1999.
View at: Publisher Site | Google Scholar
E. M. Allen, D. H. Van Boerum, A. F. Olsen, and J. M. Dean, “Difference between the measured and ordered dose of catecholamine infusions,” Annals of Pharmacotherapy, vol. 29, no. 11, pp. 1095–1100, 1995.
View at: Google Scholar
L. Rover Jr., J. C. B. Fernandes, G. de Oliveira Neto, and L. T. Kubota, “Development of a new FIA-potentiometric sensor for dopamine based on EVA-copper(II) ions,” Journal of Electroanalytical Chemistry, vol. 481, no. 1, pp. 34–41, 2000.
View at: Publisher Site | Google Scholar
F. A. Nour El-Dien, M. A. Zayed, G. G. Mohamed, and R. G. El-Nahas, “Two spectrophotometric assays for dopamine derivatives in pharmaceutical products and in biological samples of schizophrenic patients using copper tetramine complex and triiodide reagent,” Journal of Biomedicine and Biotechnology, vol. 2005, no. 1, pp. 1–9, 2005.
View at: Publisher Site | Google Scholar
Y. Chen, S. Wang, and T. Zhou, “Spectrophotometric determination of trace phenol in water after preconcentration on an organic solvent-soluble membrane filter,” Analytical Letters, vol. 31, no. 7, pp. 1233–1245, 1998.
View at: Google Scholar
F. Martin and M. Otto, “Multicomponent analysis of phenols in waste waters of the coal conversion industry by means of UV-spectrometry,” Fresenius' Journal of Analytical Chemistry, vol. 352, no. 5, pp. 451–455, 1995.
View at: Publisher Site | Google Scholar
B. Uslu and S. A. Özkan, “Determination of binary mixtures of levodopa and benserazide in pharmaceuticals by ratio-spectra derivative spectrophotometry,” Analytical Letters, vol. 35, no. 2, pp. 303–314, 2002.
View at: Publisher Site | Google Scholar
British Pharmacopoeia, volume 1, 1998.
U.S. Pharmacopeia, National Formulory, 1995.
J. C. Miller and J. N. Miller, Statistics for Analytica Chemistry, Ellis Horwood, Chichester, UK, 2nd edition, 1988.
View at: Google Scholar
K. Gobler, “HPLC, applications (Macherey-NAGel),” Dissertation, Erlangen-Nümberg, Erlangen, Germany, 1980.
View at: Google Scholar
N. C. Andreasen, W. T. Carpenter Jr., J. M. Kane, R. A. Lasser, S. R. Marder, and D. R. Weinberger, “Remission in schizophrenia: proposed criteria and rationale for consensus,” American Journal of Psychiatry, vol. 162, no. 3, pp. 441–449, 2005.
View at: Publisher Site | Google Scholar
American Psychiatric Association, Practice Guidelines for the Treatment of Patients with Schizophrenia, American Psychiatric Association, Washington, DC, USA, 1997.
View at: Google Scholar
P. J. Weiden, R. Aquila, and J. Standard, “Atypical antipsychotic drugs and long-term outcome in schizophrenia,” Journal of Clinical Psychiatry, vol. 57, supplement 11, pp. 53–60, 1996.
View at: Google Scholar
P. J. Weiden and M. Olfson, “Cost of relapse in schizophrenia,” Schizophrenia Bulletin, vol. 21, no. 3, pp. 419–429, 1995.
View at: Google Scholar
J. A. Worrel, P. A. Marken, S. E. Beckman, and V. L. Ruehter, “Atypical antipsychotic agents: a critical review,” American Journal of Health-System Pharmacy, vol. 57, no. 3, pp. 238–255, 2000.
View at: Google Scholar
G. Chouinard, B. Jones, and G. Remington et al., “A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients,” Journal of Clinical Psychopharmacology, vol. 13, no. 1, pp. 25–40, 1993.
View at: Google Scholar
J. Peuskens, V. F. Donnoli, and M. E. Portnoy et al., “Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol,” British Journal of Psychiatry, vol. 166, pp. 712–726, 1995.
View at: Google Scholar
C. M. Beasley Jr., T. Sanger, and W. Satterlee et al., “Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial,” Psychopharmacology, vol. 124, no. 1-2, pp. 159–167, 1996.
View at: Google Scholar
C. M. Beasley Jr., G. Tollefson, P. Tran, W. Satterlee, T. Sanger, and S. Hamilton, “Olanzapine versus Placebo and Haloperidol: acute phase results of the North American double-blind olanzapine trial,” Neuropsychopharmacology, vol. 14, no. 2, pp. 111–123, 1996.
View at: Google Scholar
G. D. Tollefson, C. M. Beasley, and P. V. Tran et al., “Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an International Collaborative Trial,” American Journal of Psychiatry, vol. 154, no. 4, pp. 457–465, 1997.
View at: Google Scholar
G. Remington and S.-A. Chong, “Conventional versus novel antipsychotics: changing concepts and clinical implications,” Journal of Psychiatry and Neuroscience, vol. 24, no. 5, pp. 431–441, 1999.
View at: Google Scholar
K. Wahlbeck, M. Cheine, K. Tuisku, A. Ahokas, G. Joffe, and R. Rimon, “Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 24, no. 6, pp. 911–922, 2000.
View at: Publisher Site | Google Scholar
P. Handest and J. Parnas, “Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder,” British Journal of Psychiatry, vol. 187, supplement 48, pp. s49–s54, 2005.
View at: Publisher Site | Google Scholar
Diagnostic and statistical Manual of Mental disorders, 4th ed., Text Revision, DSM-IV-TR, American Psychiatric Association, 2005.

Copyright

Copyright © 2006 Faten A. Nour El-Dien et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

241

Downloads

734

Citations